3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Solitary Fibrous Tumor, Pleural
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pleural Effusion, Malignant
1
Mesothelioma, Malignant
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
8
Carboplatin
8
Bevacizumab
8
Pleurodesis
7
Talc
6
Paclitaxel
6
Docetaxel
5
Povidone-Iodine
4
Doxycycline
4
Thoracoscopy
3
Taxes
3
Gemcitabine
3
Drug Therapy
3
Chest Tubes
3
aldesleukin
2
Zoledronic Acid
2
Trastuzumab
2
Thoracentesis
2
Surveys and Questionnaires
2
Sodium Chloride
2
Silver Nitrate
2
Pharmaceutical Preparations
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
High-Energy Shock Waves
2
Fluorodeoxyglucose F18
2
Fentanyl
2
Erlotinib Hydrochloride
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pleural Effusion, Malignant
×
rilotumumab
×
Thoracic
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts